Compare Abbott Laboratories (ABT) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Solaredge Technologies Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Solaredge Technologies Inc trades at $52.41 (market cap $3.22B). The key difference: Abbott Laboratories is far larger — about 51.8× Solaredge Technologies Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| ABT | SEDG | |
|---|---|---|
Market Cap | $166.94B | $3.22B |
Sector | Health | Technology |
52-Week High | $136.62 | $78.51 |
52-Week Low | $82.57 | $24.42 |
Enterprise Value | $193.69B | $3.15B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SolarEdge Technologies (SEDG) trades at $52.94, up 1.07% on the day, with a bullish technical signal from moving averages and recent positive momentum in solar stocks. The company reported Q1 2026 earnings that missed expectations, with a net loss of $405.45 million on $1.18 billion revenue. Despite negative profitability metrics, SEDG has beaten earnings estimates in two of the last three quarters. Recent news highlights sector-wide gains driven by AI data center power demand and analyst optimism.
The outlook remains mixed: strong solar industry tailwinds and operational cash flow improvement offer potential upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Analyst consensus is cautious with a $32.11 price target below current levels, reflecting concerns over profitability and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
